{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:59:16Z","timestamp":1789106356739,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaip.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:50:50Z","timestamp":1769619050000},"page":"613-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7928-6317","authenticated-orcid":false,"given":"Alexandra M.","family":"Nanzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.01.014_bib1","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaip.2026.01.014_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.014_bib3","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2026.01.014_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0025-6196(25)09873-8","article-title":"Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases","volume":"52","author":"Chumbley","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2026.01.014_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0002-9343(67)90144-1","article-title":"Long-term follow-up study of periarteritis nodosa","volume":"43","author":"Frohnert","year":"1967","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2026.01.014_bib8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2026.01.014_bib9","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2026.01.014_bib10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","article-title":"Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis : a randomized controlled trial","volume":"178","author":"Terrier","year":"2025","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.jaip.2026.01.014_bib11","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/jcm14124309","article-title":"High disease burden and oral corticosteroid use in patients with hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis: country-level insights into real-world management in Europe","volume":"14","author":"Hwee","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acr.22686","article-title":"Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"68","author":"Durel","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaip.2026.01.014_bib13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2026.01.014_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.014_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2026.01.014_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis","volume":"301","author":"Fauci","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib17","first-page":"567","volume":"18","author":"Guillevin","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaip.2026.01.014_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2026.01.014_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103338","article-title":"Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors","volume":"149","author":"Sorin","year":"2024","journal-title":"J Autoimmun"},{"issue":"Suppl 2","key":"10.1016\/j.jaip.2026.01.014_bib20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaip.2026.01.014_bib21","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.014_bib22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.01.014_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/rheumatology\/kead302","article-title":"Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study","volume":"63","author":"Milanesi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2026.01.014_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2026.01.014_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0038-1669454","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"39","author":"Nguyen","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"Suppl 36","key":"10.1016\/j.jaip.2026.01.014_bib26","first-page":"S52","article-title":"Churg Strauss syndrome\u2014successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaip.2026.01.014_bib27","first-page":"47","article-title":"Asthma and vasculitis. Response to intravenous immunoglobulins","volume":"21","author":"Armentia","year":"1993","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaip.2026.01.014_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00007611-199904000-00012","article-title":"Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins","volume":"92","author":"Levy","year":"1999","journal-title":"South Med J"},{"key":"10.1016\/j.jaip.2026.01.014_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1081-1206(10)61714-0","article-title":"Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin","volume":"92","author":"Tsurikisawa","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib31","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","article-title":"Eosinophil granule proteins: form and function","volume":"289","author":"Acharya","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaip.2026.01.014_bib32","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2026.01.014_bib33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"119","author":"Rosenberg","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1361.053","article-title":"Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome","volume":"1051","author":"Hellmich","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaip.2026.01.014_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/ajrccm\/aamaf135","article-title":"Fractional exhaled nitric oxide as a novel biomarker of relapse in eosinophilic granulomatosis with polyangiitis","author":"Cefaloni","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.01.014_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib37","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib38","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.014_bib39","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib40","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib41","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ard.2025.06.2131","article-title":"Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis","volume":"84","author":"Merkel","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.01.014_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/Ralpha biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaip.2024.01.006","article-title":"Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Nanzer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.014_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.01.014_bib45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaip.2026.01.014_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2026.01.014_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaci.2019.06.011","article-title":"Thymic stromal lymphopoietin epigenetically upregulates Fc receptor gamma subunit-related receptors on antigen-presenting cells and induces T(H)2\/T(H)17 polarization through dectin-2","volume":"144","author":"Liang","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.014_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chest.2025.05.015","article-title":"Tezepelumab in patients with eosinophilic granulomatosis with polyangiitis after suboptimal response to anti-IL5\/5R therapy","volume":"168","author":"Nanzer","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.014_bib49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12931-024-02888-x","article-title":"Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma","volume":"25","author":"Vincent-Galtie","year":"2024","journal-title":"Respir Res"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:50:07Z","timestamp":1781265007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2213219826000504"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.014","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}